Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

1 Dec 2021

Abstract excerpt

Prostate adenocarcinoma (PRAD) is a leading cause of death among men. Messenger ribonucleic acid (mRNA) vaccine presents an attractive approach to achieve satisfactory outcomes; however, tumor antigen screening and vaccination candidates show a bottleneck in this field. We aimed to investigate the tumor antigens for mRNA vaccine development and immune subtypes for choosing appropriate patients for vaccination. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34872584
DOI: 10.1186/s12943-021-01452-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccinePMID 34872584Read ↗

Screening of tumor antigens and immunogenic cell death landscapes of prostate cancer for exploration of mRNA vaccineSemantic proximity Read ↗

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.Semantic proximity Read ↗

Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.Semantic proximity Read ↗

Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.Semantic proximity Read ↗

Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.Semantic proximity Read ↗

Predicting Prostate Adenocarcinoma Patients’ Survival and Immune Signature: A Novel Risk Model Based on Telomere-Related GenesSemantic proximity Read ↗

Identification of tumor antigens and immune subtypes of bladder cancer for mRNA vaccine developmentSemantic proximity Read ↗

Identifying tumor antigens and immuno‐subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccineSemantic proximity Read ↗

Establishing a Prognostic Model in Prostate Adenocarcinoma through Comprehensive scRNA-Seq and Bulk RNA-Seq Analysis and ValidationSemantic proximity Read ↗

Identification of Prostate Cancer Subtypes Based on Immune Signature Scores in Bulk and Single Cell TranscriptomesSemantic proximity Read ↗

Integrated Characterization of lncRNA-Immune Interactions in Prostate CancerSemantic proximity Read ↗

Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.